Interim research results has found Race Oncology’s (RAC) Zantrene drug can protect heart muscles from anthracycline induced cell death while boost the killing of breast cancer cells
Anthracyclines are one of the most effective anti-cancer treatments developed, however can cause permanent damage
While the drug improves heart safety, the question is can it help prevent the heart damage caused by anthracyclines has never been addressed
A phase 2b trial is being planned for 2022 in breast cancer patients at high risk of anthracycline-caused heart damage
On the market this morning, Race is up 8.88 per cent and trading at $3.68 per share
Submitted November 22, 2021 at 12:23AM by kyro2000 https://ift.tt/3FBvZi7
